Physician profile
David Arnold
NPI 1003311051
$3,471.21
in general payments reported to CMS, 2019-2025
25 companies · $731 in 2025
The $731 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $104 · 2021: $163 · 2022: $697 · 2023: $877 · 2024: $899 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,407 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,407.35 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $725.54 | 2022-2025 | Botox, Skyrizi |
| Amgen INC. | $451.62 | 2022-2025 | Otezla |
| Genzyme Corporation | $350.21 | 2022-2025 | |
| Galderma Laboratories, L.P. | $312.48 | 2022-2025 | |
| Lilly USA, LLC | $300.64 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Janssen Biotech, INC. | $253.38 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $183.15 | 2020-2023 | Dupixent |
| Incyte Corporation | $178.70 | 2021-2023 | Opzelura |
| Novartis Pharmaceuticals Corporation | $158.32 | 2023-2025 | |
| Ucb, INC. | $70.11 | 2023-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $56.52 | 2022-2023 | Winlevi |
| E.R. Squibb & Sons, L.L.C. | $56.46 | 2022-2024 | Sotyktu |
| Strata Skin Sciences, INC. | $44.72 | 2025 | Xtrac |
| Dermavant Sciences, INC. | $41.42 | 2024 | Vtama |
| Pfizer INC. | $40.12 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $38.42 | 2025 | Puraply Wound Matrix |
| Krystal Biotech INC | $32.32 | 2024 | Vyjuvek |
| Fresenius Kabi USA, LLC | $27.67 | 2025 | |
| Verrica Pharmaceuticals INC. | $24.47 | 2024 | Ycanth |
| Blueprint Medicines Corporation | $23.18 | 2024 | Ayvakit |
| Kyowa Kirin, INC. | $22.31 | 2023 | Poteligeo |
| Leo Pharma INC. | $22.14 | 2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.72 | 2023 | Spevigo |
| Epi Health, LLC | $20.00 | 2022 | |
| Botanix Sb INC | $15.59 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.